Clinical Trial

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Study acronym: SuRage-EB

Withdrawn Phase 4

View on ClinicalTrials.gov →

Why the trial stopped

The study was terminated early due to insufficient patient recruitment.

Summary

This is an open-label, prospective, single arm study conducted in Germany to investigate local treatment (i.e. surgery or radiotherapy or electrochemotherapy) of metastases showing no response to encorafenib (E) + binimetinib (B) combination therapy and continuation of EB therapy afterwards. The purpose of this study is to determine PFS of individual patients treated with local intervention while continuing therapy with EB.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-07-22.

Status change: Not Yet Recruiting → Withdrawn 2026-04-16

Trial Details

NCT Number	NCT07092410
Lead Sponsor	SRH Wald-Klinikum Gera GmbH Collaborators: Pierre Fabre Pharma GmbH
Conditions	Melanoma BRAF V600E/K Mutated
Start Date	2025-08
Primary Completion	2030-08 (estimated)
Study Completion	2030-08 (estimated)
Updated on ClinicalTrials.gov	2026-04-21